Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOlDiLOX: Glofitamab and Pirtobrutinib in MCL
NCT05833763Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2023
- Primary completion
- Apr 2032
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab and pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Efficacy of combination Pirtobrutinib and Glofitamab at 18 weeks. Started Oct 2023; status: recruiting.
02
Drugs
glofitamabpirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05833763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833763.